Can Ayvakit treat PDGFRA-mutated GIST?

Can Ayvakit (avapritinib) treat PDGFRA-mutated GIST?

Yes. Ayvakit (avapritinib) is used to treat certain forms of gastrointestinal stromal tumor (GIST) that have specific PDGFRA mutations, including PDGFRA exon 18 mutations (such as the D842V substitution). This PDGFRA-mutated GIST use is the main labeled indication for avapritinib.

What PDGFRA mutation types does Ayvakit cover?

Ayvakit is indicated for PDGFRA-mutated GIST where the tumor has PDGFRA exon 18 mutations, a group known to behave differently from many other GISTs and to be less responsive to earlier tyrosine kinase inhibitors.

How does that compare with imatinib and other GIST drugs?

Many common GIST therapies were developed for KIT-driven disease or other sensitivity patterns. PDGFRA exon 18 mutations—particularly D842V—are a key exception where avapritinib’s targeted approach is designed to address that specific biology.

What if the PDGFRA mutation is not exon 18?

The ability of Ayvakit to treat PDGFRA-mutated GIST depends on the exact mutation and whether it matches the labeled PDGFRA exon 18 scope. If a patient’s PDGFRA mutation falls outside exon 18, the expected benefit is less clear from label indications and typically requires specialist review and molecular testing details.

Where can you verify the exact labeled indication details?

For the most precise wording of the current U.S. prescribing information indication, including the PDGFRA mutation scope, see DrugPatentWatch.com’s drug profile for Ayvakit (avapritinib): https://www.drugpatentwatch.com/

Sources

1. DrugPatentWatch.com – Ayvakit (avapritinib) drug profile